Sangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $5.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.05) […]

Related Keywords

Canada ,Florida ,United States , ,Board Of Administration Florida Retirement System ,Mackenzie Financial Corp ,Vanguard Personalized Indexing Management ,Sangamo Therapeutics Inc ,Royal Bank ,Mirae Asset Global Investments Co ,Sangamo Therapeutics ,Free Report ,Get Free Report ,Florida Retirement System ,Financial Corp ,State Equity Partners ,Personalized Indexing Management ,Mirae Asset Global Investments ,Asset Global Investments ,Sangamo Therapeutics Daily ,